If the stock closes at or near its peak, it would mark the largest first-day pop for a US IPO raising more than $100 million since CureVac NV in 2020. CureVac’s shares closed 249% higher in debut and continued to soar before disappointing Covid-19 vaccine data drove a collapse in the biotech’s stock price.
The offering of 34 million shares by Circle and backers including co-founder and Chief Executive Officer Jeremy Allaire was increased from 32 million shares, and had been marketed at $27 to $28 each.